由买买提看人间百态

boards

本页内容为未名空间相应帖子的节选和存档,一周内的贴子最多显示50字,超过一周显示500字 访问原贴
Biology版 - 一个对NGS-based tests持谨慎观望立场者的声音(转帖)
相关主题
全球第一家专注于癌症基因检测的公司昨天上市关于将来提高cancer治愈率的一个粗略预期
波士顿,DFCI, 招人RE: 关于将来提高cancer治愈率的一个粗略想法
大家怎么看这篇reuters的报道 关于cancer targeted therapy包子]请教各位大牛一个问题:cancer drug以后的发展方向是什么?
Personalized Cancer Medicine生物公司的实习真难找啊
Need a paper关于引物问题的请教
请教:关于肺癌治疗关于cancer genomics
迷茫的女生想转行,请过来人指点癌症基因检测应用的重磅文章来了
大家觉得genomic cancer study有前途吗?感觉很忽悠人啊NGS/Array Job opportunity -Illumina
相关话题的讨论汇总
话题: testing话题: ngs话题: therapies话题: evidence话题: treatment
进入Biology版参与讨论
1 (共1页)
h*****g
发帖数: 42
1
有些道理
...............,
H. Jack West MD, Medical Director, Thoracic Oncology Program, Swedish Cancer
Institute, Seattle, Washington
In an effort to expedite the transition into a world of molecular oncology
and precision medicine, the US Food and Drug Administration (FDA) recently
approved Foundation Medicine's next-generation sequencing (NGS)-based in
vitro diagnostic test, FoundationOnc CDx (F1CDx), which can detect genetic
mutations in 324 genes and two genomic signatures in any solid tumor type.[1
] Moreover, the Centers for Medicare & Medicaid Services (CMS) also proposed
coverage for the F1CDx test.[1] We can certainly expect this to lead to a
transformation in cancer care and a greater frequency of detection of
potentially actionable targets. At the same time, however, it is important
to recognize the limitations and potential negative, unintended consequences
of this change as well.
In the interests of full disclosure, I have previously expressed skepticism
about universal genomic sequencing,[2] on the basis of the absence of
prospective, population-based evidence that genomic testing improves any
clinically significant outcomes. This is not to say that molecular testing
has no role, particularly for patients with cancers for which we have well-
established and biomarker-dependent targeted therapies. My concerns about
universal broad genomic testing have not intended to question the utility of
"precision medicine."
Instead, my view is that we should step back from the unfettered hype to
question the presumption, still based on anecdotal or very biased
retrospective data combined with an inherent belief or bias in favor of NGS
testing, that identifying more targets is inherently better, especially if
most of these identified targets have little or no clinical data to guide an
arguably optimal targeted therapy toward them.
But regardless of whether or not there is a benefit to identifying rare
mutations with potential but unproven therapies, NGS testing represents a
more efficient use of limited tissue and becomes increasingly cost-effective
as the number of targets clearly worth testing for a given cancer grows.
For lung cancer, where EGFR, ALK, ROS1, and BRAF B600E are all indicated
tests in addition to PD-L1 expression, and with another handful of emerging
biomarkers for associated targeted therapies for which there is a critical
mass of phase 2 clinical evidence, NGS testing is a clearly compelling
option. For other cancers, in which there are few or no current molecular
markers with established utility, the benefit of testing for a wide range of
markers is more speculative.
There is good reason to be concerned that more is not necessarily better in
this setting. Although the cost of broad NGS testing itself is often cited
as a significant concern, this expense of several thousand dollars per test
is little more than a drop in the bucket in a time when we have become
inured to treatment costs often exceeding $15,000 per month. This is
especially true as technology improves and NGS testing costs may well
decline. Our bigger concern should be the financial and clinical
consequences of treatment decisions made for molecular targets without an
associated targeted therapy.
Although many respected leading figures in oncology and healthcare presume
that treatments based on molecular testing will lead to better outcomes,
this conclusion is devoid of prospective evidence. Dr William Halsted was a
renowned, commanding figure who fostered the eminence-based dogma that
disfiguring radical mastectomies were the appropriate treatment for
resectable breast cancer, and this edict was broadly accepted as self-
evident rather than subjected to critical testing for decades—to the great
harm of generations of women with breast cancer. Unfortunately, even after
centuries of what should be humility-inspiring illustrations of our hubris,
the medical community remains all too willing to grant a pass to bias-driven
conclusions from respected luminaries who speak with authority but weak
evidence. Precision medicine needs to move beyond dramatic anecdotal cases
without denominators of the population tested, or retrospective studies
working backward from collections of patients with readily targetable
lesions.
Despite the reflexive promotion of broad NGS testing as the party line by so
many of its proponents, the fact remains that a large fraction of potential
biomarkers identified by NGS testing create dark tunnels that are just as
likely to be rabbit holes leading nowhere as they are to be previously
unrecognized gold mines of remarkably beneficial and effective therapies for
new or future targets. In an effort to provide treatment options and
justify the cost of testing that all too often delivers no evidence-based
therapy recommendations, NGS reports from Foundation Medicine and many
others offer treatment options based on very early clinical trials or even
preclinical data. Whether broad genomic testing becomes a beneficial
inflection point for improving cancer care or a key moment where treatment
costs come off the rails depends entirely on whether the reported results
are interpreted judiciously or with an uncritical, gravitational pull toward
molecularly defined therapies.
At a time when we face difficult decisions about how to cover the societal
costs of very expensive cancer treatments with well-established benefits, we
should be wary of increasing these challenges by selecting very expensive
therapies devoid of strong clinical evidence. A few months of completely
speculative, low-yield treatment with a targeted therapy that costs tens of
thousands of dollars on the basis of a preclinically driven premise has the
potential to create a societal financial nightmare if we expect these costs
to be borne by insurers, who will invariably pass the costs on to their
subscribers, now unwittingly forced to bankroll ill-advised decisions.
But the potential harm is not merely financial and indirectly borne by
society. First, these targeted therapies may have significant adverse
effects and lead to unexpected detrimental effects. Nobody in the lung
cancer community expected gefitinib to be associated with a significantly
detrimental effect after chemotherapy and radiation that amounted to a 12-
month shorter survival than with placebo,[3] even if we might have thought
that it may or may not help. But even beyond the potential for harm from a
targeted therapy compared with placebo or supportive care, I too often see
colleagues displace standard-of-care, established treatments with ones
inspired by NGS reports indicating benefits that should be considered more
in the range of "fanciful" than "expected"-a poor trade that may lead to
worse outcomes rather than better ones, especially if this decision is made
in an earlier line when treatments with meaningful and proven benefits are
bypassed.
Despite these concerns, I recognize the great potential for broad genomic
testing to accelerate the rate of cancer research and identify subsets of
patients likely to benefit profoundly. The key lies in the ability of
clinicians to discriminate the quality of the evidence and judge the merit
of the therapeutic recommendation accordingly. An important model of this
approach has been published[4] and distinguishes among treatments that are
ranked from level 1 (FDA-approved) to level 2 (standard care), level 3 (
clinical evidence), and level 4 (biological evidence). Following the
threshold for these criteria makes good sense in helping to distinguish what
to expect to be covered by insurers compared with other options. Those
options at a higher level, with relatively weaker evidence, may still
present a strong strategy in the setting of a clinical trial, compassionate
use program, or self-payment for a targeted therapy; but they should be
acknowledged as falling short of the standards that should compel insurance
coverage or substitution for treatment options with clinical data
demonstrating a benefit in treatment outcomes.
Of note, we must also maintain rigor in our endpoints and demand that the
benefits measured are clinically meaningful, such as a significant
improvement in overall survival, rather than manufacturing new, weak
endpoints-for example, a relative gain in progression-free survival compared
with ineffective alternative salvage therapies, which have been created
merely as a very low bar for tested therapies to exceed. For the cost of
these treatments and the promise we have offered from precision medicine
approaches, we should test endpoints that do more than create meaningless
feel-good victories.
Rather than continuing to debate whether broad genomic testing should be
done for patients with solid tumors, I feel that ship has sailed. But
whether it takes us to a new world or we end up under water depends on how
we direct that ship from here.
References
h*****g
发帖数: 42
2
有些道理
...............,
H. Jack West MD, Medical Director, Thoracic Oncology Program, Swedish Cancer
Institute, Seattle, Washington
In an effort to expedite the transition into a world of molecular oncology
and precision medicine, the US Food and Drug Administration (FDA) recently
approved Foundation Medicine's next-generation sequencing (NGS)-based in
vitro diagnostic test, FoundationOnc CDx (F1CDx), which can detect genetic
mutations in 324 genes and two genomic signatures in any solid tumor type.[1
] Moreover, the Centers for Medicare & Medicaid Services (CMS) also proposed
coverage for the F1CDx test.[1] We can certainly expect this to lead to a
transformation in cancer care and a greater frequency of detection of
potentially actionable targets. At the same time, however, it is important
to recognize the limitations and potential negative, unintended consequences
of this change as well.
In the interests of full disclosure, I have previously expressed skepticism
about universal genomic sequencing,[2] on the basis of the absence of
prospective, population-based evidence that genomic testing improves any
clinically significant outcomes. This is not to say that molecular testing
has no role, particularly for patients with cancers for which we have well-
established and biomarker-dependent targeted therapies. My concerns about
universal broad genomic testing have not intended to question the utility of
"precision medicine."
Instead, my view is that we should step back from the unfettered hype to
question the presumption, still based on anecdotal or very biased
retrospective data combined with an inherent belief or bias in favor of NGS
testing, that identifying more targets is inherently better, especially if
most of these identified targets have little or no clinical data to guide an
arguably optimal targeted therapy toward them.
But regardless of whether or not there is a benefit to identifying rare
mutations with potential but unproven therapies, NGS testing represents a
more efficient use of limited tissue and becomes increasingly cost-effective
as the number of targets clearly worth testing for a given cancer grows.
For lung cancer, where EGFR, ALK, ROS1, and BRAF B600E are all indicated
tests in addition to PD-L1 expression, and with another handful of emerging
biomarkers for associated targeted therapies for which there is a critical
mass of phase 2 clinical evidence, NGS testing is a clearly compelling
option. For other cancers, in which there are few or no current molecular
markers with established utility, the benefit of testing for a wide range of
markers is more speculative.
There is good reason to be concerned that more is not necessarily better in
this setting. Although the cost of broad NGS testing itself is often cited
as a significant concern, this expense of several thousand dollars per test
is little more than a drop in the bucket in a time when we have become
inured to treatment costs often exceeding $15,000 per month. This is
especially true as technology improves and NGS testing costs may well
decline. Our bigger concern should be the financial and clinical
consequences of treatment decisions made for molecular targets without an
associated targeted therapy.
Although many respected leading figures in oncology and healthcare presume
that treatments based on molecular testing will lead to better outcomes,
this conclusion is devoid of prospective evidence. Dr William Halsted was a
renowned, commanding figure who fostered the eminence-based dogma that
disfiguring radical mastectomies were the appropriate treatment for
resectable breast cancer, and this edict was broadly accepted as self-
evident rather than subjected to critical testing for decades—to the great
harm of generations of women with breast cancer. Unfortunately, even after
centuries of what should be humility-inspiring illustrations of our hubris,
the medical community remains all too willing to grant a pass to bias-driven
conclusions from respected luminaries who speak with authority but weak
evidence. Precision medicine needs to move beyond dramatic anecdotal cases
without denominators of the population tested, or retrospective studies
working backward from collections of patients with readily targetable
lesions.
Despite the reflexive promotion of broad NGS testing as the party line by so
many of its proponents, the fact remains that a large fraction of potential
biomarkers identified by NGS testing create dark tunnels that are just as
likely to be rabbit holes leading nowhere as they are to be previously
unrecognized gold mines of remarkably beneficial and effective therapies for
new or future targets. In an effort to provide treatment options and
justify the cost of testing that all too often delivers no evidence-based
therapy recommendations, NGS reports from Foundation Medicine and many
others offer treatment options based on very early clinical trials or even
preclinical data. Whether broad genomic testing becomes a beneficial
inflection point for improving cancer care or a key moment where treatment
costs come off the rails depends entirely on whether the reported results
are interpreted judiciously or with an uncritical, gravitational pull toward
molecularly defined therapies.
At a time when we face difficult decisions about how to cover the societal
costs of very expensive cancer treatments with well-established benefits, we
should be wary of increasing these challenges by selecting very expensive
therapies devoid of strong clinical evidence. A few months of completely
speculative, low-yield treatment with a targeted therapy that costs tens of
thousands of dollars on the basis of a preclinically driven premise has the
potential to create a societal financial nightmare if we expect these costs
to be borne by insurers, who will invariably pass the costs on to their
subscribers, now unwittingly forced to bankroll ill-advised decisions.
But the potential harm is not merely financial and indirectly borne by
society. First, these targeted therapies may have significant adverse
effects and lead to unexpected detrimental effects. Nobody in the lung
cancer community expected gefitinib to be associated with a significantly
detrimental effect after chemotherapy and radiation that amounted to a 12-
month shorter survival than with placebo,[3] even if we might have thought
that it may or may not help. But even beyond the potential for harm from a
targeted therapy compared with placebo or supportive care, I too often see
colleagues displace standard-of-care, established treatments with ones
inspired by NGS reports indicating benefits that should be considered more
in the range of "fanciful" than "expected"-a poor trade that may lead to
worse outcomes rather than better ones, especially if this decision is made
in an earlier line when treatments with meaningful and proven benefits are
bypassed.
Despite these concerns, I recognize the great potential for broad genomic
testing to accelerate the rate of cancer research and identify subsets of
patients likely to benefit profoundly. The key lies in the ability of
clinicians to discriminate the quality of the evidence and judge the merit
of the therapeutic recommendation accordingly. An important model of this
approach has been published[4] and distinguishes among treatments that are
ranked from level 1 (FDA-approved) to level 2 (standard care), level 3 (
clinical evidence), and level 4 (biological evidence). Following the
threshold for these criteria makes good sense in helping to distinguish what
to expect to be covered by insurers compared with other options. Those
options at a higher level, with relatively weaker evidence, may still
present a strong strategy in the setting of a clinical trial, compassionate
use program, or self-payment for a targeted therapy; but they should be
acknowledged as falling short of the standards that should compel insurance
coverage or substitution for treatment options with clinical data
demonstrating a benefit in treatment outcomes.
Of note, we must also maintain rigor in our endpoints and demand that the
benefits measured are clinically meaningful, such as a significant
improvement in overall survival, rather than manufacturing new, weak
endpoints-for example, a relative gain in progression-free survival compared
with ineffective alternative salvage therapies, which have been created
merely as a very low bar for tested therapies to exceed. For the cost of
these treatments and the promise we have offered from precision medicine
approaches, we should test endpoints that do more than create meaningless
feel-good victories.
Rather than continuing to debate whether broad genomic testing should be
done for patients with solid tumors, I feel that ship has sailed. But
whether it takes us to a new world or we end up under water depends on how
we direct that ship from here.
References
g********4
发帖数: 16
3
问题是如果不用NGS,那还有什么办法呢?其他的high throughput都大同小异。
-----------------------------------------------------------------------------
[微offer]:打造最好的海外博士/博士后求职招聘公众号平台!完全免费,欢迎PI来发
布信息。由一波热心的海外博士一起义务创建并维护。欢迎扫码论坛头像或者微信搜索
“微offer”进行关注联系。
s******s
发帖数: 13035
4
感觉观点就是一小部分位点很重要,很多的biomarker结果可能没有
显著clinical impact。这个就是扯淡
首先,那一小部分的价值就够了,FMI的其他位点都是free给你的,
这个价格会越来越便宜,其他非NGS的测一两个位点assay也便宜
不到哪里去
其次,对很多位点的认识不足,或者biomarker的发现不足,正是
因为测序不够多。试想一下每个癌症病人都测序,甚至每个病人
都测序,和clinical data合并出来能导致多少新biomarker的发现!

Cancer
[1
proposed

【在 h*****g 的大作中提到】
: 有些道理
: ...............,
: H. Jack West MD, Medical Director, Thoracic Oncology Program, Swedish Cancer
: Institute, Seattle, Washington
: In an effort to expedite the transition into a world of molecular oncology
: and precision medicine, the US Food and Drug Administration (FDA) recently
: approved Foundation Medicine's next-generation sequencing (NGS)-based in
: vitro diagnostic test, FoundationOnc CDx (F1CDx), which can detect genetic
: mutations in 324 genes and two genomic signatures in any solid tumor type.[1
: ] Moreover, the Centers for Medicare & Medicaid Services (CMS) also proposed

1 (共1页)
进入Biology版参与讨论
相关主题
请高手科普测序技术Need a paper
Help: 怎样sequencing一个基因的genome 序列?请教:关于肺癌治疗
About copy number variation迷茫的女生想转行,请过来人指点
求科普Next Generation Sequence大家觉得genomic cancer study有前途吗?感觉很忽悠人啊
全球第一家专注于癌症基因检测的公司昨天上市关于将来提高cancer治愈率的一个粗略预期
波士顿,DFCI, 招人RE: 关于将来提高cancer治愈率的一个粗略想法
大家怎么看这篇reuters的报道 关于cancer targeted therapy包子]请教各位大牛一个问题:cancer drug以后的发展方向是什么?
Personalized Cancer Medicine生物公司的实习真难找啊
相关话题的讨论汇总
话题: testing话题: ngs话题: therapies话题: evidence话题: treatment